Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer

por Ferrando-Díez, Angelica, Felip, Eudald, Pous, Anna, Bergamino Sirven, Milana, Margelí, Mireia
Publicado 2022

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinica...

por Bernat-Peguera, Adrià, Trigueros, Macedonia, Ferrando-Díez, Angélica, Ibáñez, Cristina, Bystrup, Sara, Martínez-Cardús, Anna, Margelí, Mireia, Martínez-Balibrea, Eva
Publicado 2022